3/25
08:00 am
ppbt
Purple Biotech Announces AI Collaboration with Converge Bio to Accelerate Development of its Next-Generation Tri-Specific Antibody Platform
Medium
Report
Purple Biotech Announces AI Collaboration with Converge Bio to Accelerate Development of its Next-Generation Tri-Specific Antibody Platform
3/17
07:12 am
ppbt
Yahoo Finance [Yahoo! Finance]
Low
Report
Yahoo Finance [Yahoo! Finance]
3/17
07:00 am
ppbt
Purple Biotech Regains Compliance with Nasdaq
Low
Report
Purple Biotech Regains Compliance with Nasdaq
3/17
06:52 am
ppbt
Purple Biotech (PPBT) was downgraded by Zacks Research from "hold" to "strong sell".
Low
Report
Purple Biotech (PPBT) was downgraded by Zacks Research from "hold" to "strong sell".
3/16
08:03 am
ppbt
Purple Biotech (PPBT) had its price target lowered by HC Wainwright from $34.00 to $30.00. They now have a "buy" rating on the stock.
Low
Report
Purple Biotech (PPBT) had its price target lowered by HC Wainwright from $34.00 to $30.00. They now have a "buy" rating on the stock.
3/13
08:36 am
ppbt
Purple Biotech Announces CEO Transition [Yahoo! Finance]
Medium
Report
Purple Biotech Announces CEO Transition [Yahoo! Finance]
3/13
08:04 am
ppbt
Purple Biotech Announces CEO Transition
Medium
Report
Purple Biotech Announces CEO Transition
3/13
08:00 am
ppbt
Purple Biotech Reports Fourth Quarter and Full Year 2025 Financial Results
Medium
Report
Purple Biotech Reports Fourth Quarter and Full Year 2025 Financial Results
2/25
04:20 pm
ppbt
Purple Biotech Announces Plan to Implement ADS Ratio Change
Medium
Report
Purple Biotech Announces Plan to Implement ADS Ratio Change
1/7
08:00 am
ppbt
Purple Biotech Achieves Toxicology Milestone Demonstrating an Expanded Therapeutic Window for CAPTN-3 Platform Tri-specific Antibody, IM1240
Low
Report
Purple Biotech Achieves Toxicology Milestone Demonstrating an Expanded Therapeutic Window for CAPTN-3 Platform Tri-specific Antibody, IM1240
12/30
04:14 pm
ppbt
Purple Biotech (NASDAQ:PPBT) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Purple Biotech (NASDAQ:PPBT) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.